[Press release] Mirum Pharmaceuticals announces primary endpoint met in Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus
Mirum Pharmaceuticals reported that its Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus met its primary endpoint. The 48-week Phase 2b data showed deepening viral suppression and increased ALT normalization. AZURE-1 is part of the U.S. registration package for brelovitug.
How this was made
![[Press release] Mirum Pharmaceuticals announces primary endpoint met in Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus — source image](/_next/image?url=%2Fdata%2Fnews-image%3Furl%3Dhttps%253A%252F%252Fwww.eatg.org%252Fwp-content%252Fuploads%252F2025%252F03%252Fclinical-trial-icon-gaac45ea20-1280.png&w=2048&q=75){kind=icon}
The 30-second read
Why it matters
The primary endpoint success positions the company for a U.S. NDA filing, which could materially affect valuation.
Market read
Positive Phase 3 data is a high‑impact catalyst for Mirum and may influence related biotech stocks.
What to watch
Potential competition from other HDV programs and the need for a US filing strategy.
Background
Mirum Pharmaceuticals is a Nasdaq‑listed biotech focused on hepatitis B and delta virus treatments.
Ticker impact
Mirum Pharmaceuticals announced its Phase 3 AZURE-1 primary endpoint was met for brelovitug, a first-in-class HDV therapy.
upward pressure as the market prices in the successful trial outcome
Phase 3 success is a material catalyst for a biotech; no comparable data has been released yet.
Market effects
May boost sentiment for HDV and hepatitis B therapeutic space.
US biotech sector could see modest gains.
Limited to investors tracking hepatitis therapies.
Counterpoint
If regulatory scrutiny intensifies or data replication fails, the rally could be short-lived.
Key entities
- companyMirum Pharmaceuticals, Inc.
Developer of brelovitug, a monoclonal antibody targeting HBsAg.
